NCT05969743 is a Phase 2 clinical trial of Letermovir in Graft-versus-host-disease, sponsored by Rabin Medical Center.

Who is sponsoring NCT05969743?

NCT05969743 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT05969743?

Interventions in NCT05969743: Letermovir.

What condition does NCT05969743 study?

NCT05969743 studies Graft-versus-host-disease, CMV.

Is NCT05969743 still recruiting?

NCT05969743 is currently status unknown. Last updated 1 August 2023.

Last reviewed 2023-08-01 · How we verify

NCT05969743

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

Status unknown Phase 2 Last updated 1 August 2023

What this trial tests

Phase 2 trial testing Letermovir in Graft-versus-host-disease in 42 participants. Status unknown.

Timeline

1 October 2023

Primary endpoint
30 April 2025

31 July 2025

Quick facts

Lead sponsor	Rabin Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	42
Start date	1 October 2023
Primary completion	30 April 2025
Estimated completion	31 July 2025

Drugs / interventions tested

Letermovir (LETERMOVIR) — full drug profile →

Conditions studied

Graft-versus-host-disease — all drugs for Graft-versus-host-disease →
CMV — all drugs for CMV →

Sponsor

Rabin Medical Center

Who can join

Adults 18 to 120, any sex, with Graft-versus-host-disease or CMV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Letermovir

Trials testing the same drug.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07199465 — A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) · Phase 1 · recruiting
NCT07488728 — Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A · NA · recruiting
NCT07079735 — Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant · Phase 2, PHASE3 · recruiting
NCT06920251 — Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy · Phase 2 · recruiting

Other recruiting trials for Graft-versus-host-disease

Currently open trials in the same condition.

NCT06008808 — Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S · Phase 1 · recruiting
NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
NCT03842696 — Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood an · Phase 1, PHASE2 · active not recruiting
NCT04337515 — A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant · NA · recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05969743 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 1 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05969743.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing